Session Information

  • WCLC 2020

    2020 World Conference on Lung Cancer

    Conference Program for the 2020 World Conference on Lung Cancer in Singapore


    Presentation Date(s):  
    • January 28 - 31, 2021
    • Total Presentations: 1597

    All times listed are in Singapore time (GMT+8)

    PL - Plenary
    PS - Presidential Symposium
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    IS - Industry Symposium
    JICC - Joint IASLC-CAALC-CSCO Session

Filter Results:

Show Only CME Accredited Sessions

  • +

    ES04 - Strategies to Increase Cure Rates in Stage III NSCLC: Optimising Checkpoint Inhibitors and Beyond

    • 11:45 - 12:45
    • 1/29/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Educational Session
    • Track: Locoregional and Oligometastatic Disease
    • +

      ES04.03 - Extending Durvalumab Maintenance to Special Populations

      12:25 - 12:45  |  Presenter: Raffaele Califano

      • Abstract

      No abstract available for this presentation

  • +

    PS01 - Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)

    • 07:00 - 09:00
    • 1/30/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PS01.09 - Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598

      08:08 - 08:18  |  Presenter: Michael Boyer

      • Abstract

      Loading...

    • +

      PS01.11 - Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial

      08:26 - 08:36  |  Presenter: Dean Fennell

      • Abstract

      Loading...

  • +

    PS02 - Presidential Symposium (Re-Broadcast) (Japanese, Mandarin, Spanish Translation Available)

    • 18:00 - 20:00
    • 1/30/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PS02.09 - Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598

      19:08 - 19:18  |  Presenter: Michael Boyer

      • Abstract

      Loading...

    • +

      PS02.11 - Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial

      19:26 - 19:36  |  Presenter: Dean Fennell

      • Abstract

      Loading...